1. a) Define hypertriglyceridemia and classify it according to fasting serum triglyceride levels. (10 marks ) b) Describe the genetic and secondary causes of hypertriglyceridemia, citing key molecular mechanisms. (10 marks) c) Describe the role of coronary calcium scoring and CT angiography. (10 marks )
Reading File
Finding Sources
Finding Sources
Finding Sources
Searching PubMed
hypertriglyceridemia
Searching the Web
2025 ACC AHA coronary artery calcium scoring coronary CT angiography guideline clinical use
Reading File
Finding Sources
Finding Sources
Finding Sources
Searching the Web
2021 AHA ACC chest pain guideline CCTA stable chest pain coronary artery calcium low risk official summary
1(a) Definition and classification of hypertriglyceridemia
Hypertriglyceridemia is an elevation of fasting plasma triglyceride (TG) concentration above the normal reference range, conventionally ≥150 mg/dL (≥1.7 mmol/L). It reflects an excess of triglyceride-rich lipoproteins, mainly very-low-density lipoprotein (VLDL) and chylomicrons.
Classification by fasting serum triglyceride level
| Category | Fasting TG, mg/dL | mmol/L | Clinical implication |
|---|---|---|---|
| Normal | <150 | <1.7 | Normal |
| Borderline high | 150-199 | 1.7-2.2 | Often associated with insulin resistance and cardiometabolic risk |
| High | 200-499 | 2.3-5.6 | Increased atherosclerotic cardiovascular disease risk; usually VLDL excess |
| Very high | ≥500 | ≥5.6 | Chylomicronemia may occur; pancreatitis risk increases |
| Severe | 1,000-1,999 | 11.3-22.5 | Major risk of acute pancreatitis |
| Very severe | ≥2,000 | ≥22.6 | Usually marked chylomicronemia; very high pancreatitis risk |
A clinically useful contemporary grouping is:
- Mild-moderate: 150-499 mg/dL
- Severe: ≥500 mg/dL
- Very severe/chylomicronemia range: ≥1,000 mg/dL
The major clinical concern at lower levels is ASCVD risk from remnant lipoproteins, whereas at TG ≥500 mg/dL, particularly ≥1,000 mg/dL, prevention of acute pancreatitis becomes the immediate priority.
Source: The Washington Manual of Medical Therapeutics, “Hypertriglyceridemia,” lines 3170-3180.
Source: The Washington Manual of Medical Therapeutics, “Hypertriglyceridemia,” lines 3170-3180.
1(b) Genetic and secondary causes, with molecular mechanisms
Plasma TG rises through one or both of two mechanisms:
- Increased hepatic production of VLDL, or
- Reduced lipolysis and clearance of chylomicrons/VLDL remnants.
A. Genetic causes
1. Familial chylomicronemia syndrome
This is a rare autosomal recessive disorder causing profound fasting chylomicronemia, usually with TG >1,000 mg/dL from childhood.
| Gene/protein affected | Molecular role | Effect of defect |
|---|---|---|
| LPL | Lipoprotein lipase hydrolyses TG in chylomicrons and VLDL at capillary endothelium | Failure of hydrolysis and clearance of TG-rich particles |
| APOC2 | ApoC-II is an obligatory cofactor that activates LPL | Functional LPL deficiency |
| APOA5 | Facilitates LPL-mediated TG clearance | Impaired lipolysis, elevated TG |
| GPIHBP1 | Transports and anchors LPL on the luminal surface of capillary endothelial cells | LPL cannot act effectively on circulating chylomicrons |
| LMF1 | Required for maturation/folding of LPL | Reduced functional LPL activity |
Clinical features: recurrent pancreatitis, eruptive xanthomas, lipemia retinalis, hepatosplenomegaly, and milky plasma. Premature ASCVD is less prominent than in remnant-particle disorders because chylomicrons are too large to enter the arterial wall.
2. Multifactorial/polygenic severe hypertriglyceridemia
This is much more common. Multiple common TG-raising variants combine with obesity, diabetes, alcohol, pregnancy, or drugs. Variants may involve APOA5, APOC3, ANGPTL3, ANGPTL4, LPL, and other regulators of VLDL metabolism.
- ApoC-III excess inhibits LPL activity and hepatic uptake of TG-rich remnants.
- ANGPTL3/ANGPTL4 excess inhibits LPL.
- The resulting phenotype is often unmasked only after a metabolic stressor.
3. Familial hypertriglyceridemia
Usually polygenic and characterized by hepatic overproduction of VLDL. It commonly produces TG around 200-1,000 mg/dL and becomes more pronounced with obesity, insulin resistance, diabetes, alcohol intake, or high-carbohydrate diets.
4. Familial combined hyperlipidemia
A common polygenic disorder with increased hepatic production of apoB-containing particles, including VLDL. Phenotypes vary within and between families: high LDL-C, high TG, or both. It is strongly associated with premature ASCVD.
5. Familial dysbetalipoproteinemia, type III hyperlipoproteinemia
Usually occurs in a person homozygous for APOE2 with an additional metabolic trigger such as obesity, diabetes, hypothyroidism, or menopause.
- ApoE normally permits hepatic clearance of chylomicron remnants and VLDL remnants.
- ApoE2 binds poorly to remnant receptors.
- Consequently, cholesterol- and TG-rich remnant particles accumulate, causing mixed hyperlipidemia and premature peripheral and coronary atherosclerosis.
Goldman-Cecil notes that apoE2 homozygosity impairs VLDL clearance and typically needs a secondary factor before overt severe dyslipidemia develops. Goldman-Cecil Medicine, “Familial Dysbetalipoproteinemia,” section at line 13370.
B. Secondary causes
| Secondary cause | Key molecular mechanism |
|---|---|
| Obesity and metabolic syndrome | Increased free fatty-acid flux to liver leads to increased hepatic TG synthesis and VLDL secretion; insulin resistance also reduces LPL-mediated clearance. |
| Type 2 diabetes mellitus, especially uncontrolled | Insulin resistance increases adipose lipolysis and hepatic VLDL synthesis. Relative insulin deficiency reduces LPL activity, impairing chylomicron/VLDL clearance. |
| Type 1 diabetes mellitus with insulin deficiency/DKA | Marked reduction in LPL activity plus enhanced adipose lipolysis can cause severe hypertriglyceridemia. |
| Alcohol excess | Increases hepatic NADH, promotes fatty-acid and TG synthesis, increases VLDL secretion, and may impair fatty-acid oxidation. It is a frequent precipitant of pancreatitis in genetically predisposed people. |
| High refined-carbohydrate/fructose intake | Stimulates hepatic de novo lipogenesis, increasing TG synthesis and VLDL output. |
| Hypothyroidism | Reduced LPL activity and impaired hepatic clearance of TG-rich remnants. |
| Chronic kidney disease/nephrotic syndrome | Reduced catabolism of VLDL/chylomicrons due to impaired LPL pathway; nephrotic syndrome additionally increases hepatic lipoprotein production. |
| Liver disease | Fatty liver and insulin resistance increase hepatic TG production and VLDL export. |
| Pregnancy | Estrogen-driven increase in hepatic VLDL production, combined with relatively reduced LPL activity in late pregnancy. Severe disease is more likely with an underlying genetic predisposition. |
| Cushing syndrome/acromegaly | Insulin resistance increases FFA delivery to liver and increases VLDL synthesis. |
| Autoimmune disease/inflammation | Cytokine-mediated inhibition of LPL and altered hepatic lipoprotein metabolism. |
Drug-induced hypertriglyceridemia
Common drugs include:
- Estrogens, particularly oral estrogen
- Glucocorticoids
- Nonselective beta-blockers
- Thiazide diuretics
- Retinoids, especially isotretinoin
- Tamoxifen
- Cyclosporine, tacrolimus, sirolimus
- Protease-inhibitor antiretroviral therapy
- Atypical antipsychotics, such as olanzapine and clozapine
- Bile-acid sequestrants, in susceptible patients
Mechanistically, these agents may increase VLDL production, worsen insulin resistance, increase adipose lipolysis, reduce LPL activity, or impair remnant clearance. The Washington Manual specifically lists obesity, diabetes, renal insufficiency, oral estrogen, glucocorticoids, beta-blockers, tamoxifen, cyclosporine, antiretrovirals, and retinoids as important causes. The Washington Manual of Medical Therapeutics, “Hypertriglyceridemia,” lines 3170-3180.
Key point: Severe hypertriglyceridemia is commonly multifactorial: a polygenic susceptibility or heterozygous LPL-pathway variant is combined with diabetes, obesity, alcohol, pregnancy, or a TG-raising medication.
A recent systematic review of severe hypertriglyceridemia supports the importance of LPL-pathway genes, including LPL, APOC2, APOA5, GPIHBP1, APOC3, and ANGPTL3 in genetic assessment (2025 systematic review, PMID: 41300829).
1(c) Role of coronary calcium scoring and CT coronary angiography
1. Coronary artery calcium scoring, CAC
Coronary artery calcium scoring is a non-contrast, ECG-gated CT examination that detects and quantifies calcified coronary plaque. The score is commonly expressed as the Agatston score, based on area and density of coronary calcification.
It is a marker of the total burden of coronary atherosclerosis, not a direct measurement of luminal stenosis.
CAC score interpretation
| Agatston score | Interpretation |
|---|---|
| 0 | No detectable calcified plaque; very low short-term event risk, though non-calcified plaque may still be present |
| 1-99 | Mild coronary atherosclerosis |
| 100-299 | Moderate plaque burden; ASCVD risk is increased |
| ≥300, or ≥75th percentile for age/sex | High plaque burden and high ASCVD risk |
| ≥1,000 | Very extensive atherosclerosis and very high event risk |
Clinical roles of CAC
-
Primary prevention risk refinement
CAC is most useful when the decision to begin or intensify statin therapy is uncertain, especially in asymptomatic adults with borderline or intermediate estimated ASCVD risk. -
Guiding preventive therapy
- CAC = 0: may support deferring statin therapy in selected patients after considering diabetes, smoking, strong family history of premature ASCVD, and other high-risk features.
- CAC 1-99: favors statin therapy, particularly in older adults.
- CAC ≥100 or ≥75th percentile: supports statin therapy and intensive risk-factor modification.
-
Assessment of low-risk stable chest pain
In a low-risk patient with stable chest pain and no known CAD, CAC can be used as a first-line test to exclude calcified plaque and identify a low likelihood of obstructive CAD. -
Risk communication and adherence
Demonstrating plaque may help patients understand their risk and improve acceptance of preventive therapy.
Limitations of CAC
- It does not image non-calcified plaque.
- A CAC score of zero does not completely exclude CAD, especially in younger people, smokers, diabetics, and patients with acute symptoms.
- It does not identify the exact site or severity of coronary stenosis.
- It is not the preferred test for evaluating suspected acute coronary syndrome.
- Radiation exposure is low but present, typically about 1 mSv.
Schwartz describes CAC as a non-contrast CT index of atherosclerotic burden based on Hounsfield-unit measurement. It is sensitive for angiographic stenosis but nonspecific because calcification may precede important luminal narrowing. Schwartz’s Principles of Surgery, 11th ed., “Diagnostic Studies,” lines 2193-2196.
2. Coronary CT angiography, CCTA
CCTA is an ECG-gated contrast-enhanced CT scan that directly visualizes the coronary lumen, coronary arterial wall, calcified and non-calcified plaque, and the presence and severity of coronary stenosis.
Roles of CCTA
-
Diagnosis of coronary artery disease in stable chest pain
CCTA is particularly useful in patients with no known CAD who have intermediate pretest probability of obstructive CAD. It can exclude significant CAD with a high negative predictive value. -
Anatomic assessment CCTA can show:
- Normal arteries
- Non-obstructive plaque
- Obstructive stenosis
- Plaque location and extent
- Calcified, non-calcified, and mixed plaques
- High-risk plaque features, such as positive remodeling and low-attenuation plaque
-
Risk stratification and preventive treatment
Detection of even non-obstructive CAD identifies patients who merit intensive risk-factor control, statin therapy, and other guideline-directed preventive measures. -
Evaluation of acute chest pain in selected patients
In low-to-intermediate risk acute chest pain without known CAD, CCTA can rapidly exclude obstructive CAD. In selected emergency settings, it may form part of a “triple-rule-out” evaluation for coronary disease, pulmonary embolism, and aortic dissection. -
Evaluation of coronary anomalies and bypass grafts
It is useful for congenital coronary anomalies and can assess bypass graft patency. It may also be useful for selected stent assessments, although heavy calcification and small stent diameter reduce accuracy.
Limitations of CCTA
- Requires iodinated contrast, so caution is needed in significant renal dysfunction and prior severe contrast reaction.
- Image quality may be reduced by tachycardia, arrhythmia, obesity, motion, and extensive calcification.
- Very heavy coronary calcification may create blooming artifact and overestimate stenosis.
- It defines anatomy but does not necessarily establish whether a stenosis causes ischemia. Intermediate lesions may need CT-derived fractional flow reserve, stress imaging, or invasive angiography.
- Radiation exposure is generally higher than CAC scoring, although modern protocols can substantially reduce dose.
The ACC chest-pain guideline summary states that CCTA is useful for diagnosis and risk stratification in patients with stable chest pain and intermediate-high risk who have no known CAD. It also supports CAC as a first-line option to exclude calcific plaque in selected low-risk stable chest-pain patients.
CAC versus CCTA
| Feature | CAC score | CCTA |
|---|---|---|
| Contrast | No | Yes, iodinated contrast |
| What it detects | Calcified plaque burden | Lumen, stenosis, calcified and non-calcified plaque |
| Main use | Preventive risk reclassification | Diagnostic evaluation of suspected CAD |
| Stenosis assessment | Indirect and limited | Direct anatomic assessment |
| Radiation | Low | Higher, but protocol dependent |
| Best clinical setting | Asymptomatic/borderline-intermediate prevention risk; selected low-risk stable chest pain | Intermediate-risk stable chest pain or selected acute chest pain |
Summary: CAC answers, “How much calcified atherosclerosis is present and what is the future risk?” CCTA answers, “Is coronary plaque or stenosis present, where is it, and how severe is it?”
This is a shared conversation. Sign in to Orris to start your own chat.